Добірка наукової літератури з теми "Agents anti-infectieux – Chez l'enfant"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Agents anti-infectieux – Chez l'enfant".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Agents anti-infectieux – Chez l'enfant":
Al Dughayrn, A. M., A. I. Afaleq, and A. M. Homeida. "Synthèse sur les effets indésirables de certains médicaments chez le chameau." Revue d’élevage et de médecine vétérinaire des pays tropicaux 51, no. 1 (January 1, 1998): 81–86. http://dx.doi.org/10.19182/remvt.9657.
Carrié, Cédric, Noémie Sauvage та Matthieu Biais. "Optimisation du traitement par β-Lactamines chez le patient de réanimation en hyperclairance rénale". Médecine Intensive Réanimation 30, № 2 (18 травня 2021): 157–64. http://dx.doi.org/10.37051/mir-00059.
Pai, Alexander, Zahra Kanji, and James Joshua Douglas. "Characterization of Coinfections in Patients with COVID-19." Canadian Journal of Hospital Pharmacy 77, no. 1 (January 10, 2024). http://dx.doi.org/10.4212/cjhp.3398.
Mihajlovic, Silvija, Jeremie Gauthier, and Erika MacDonald. "Patient Characteristics Associated with Adverse Drug Events in Hospital: An Overview of Reviews." Canadian Journal of Hospital Pharmacy 69, no. 4 (August 31, 2016). http://dx.doi.org/10.4212/cjhp.v69i4.1583.
Дисертації з теми "Agents anti-infectieux – Chez l'enfant":
Ponthier, Laure. "Application des approches de modelisation et de machine learning a l'individualisation des doses d’anti-infectieux en pediatrie." Electronic Thesis or Diss., Limoges, 2023. http://www.theses.fr/2023LIMO0098.
Initially, we developed a Machine learning (ML) algorithm based on pharmacokinetic profiles obtained by Monte Carlo simulations using a population pharmacokinetic model (POPPK) from the literature, in order to derive the best vancomycin initial dose in preterm and term neonates. We compared ML performances with those of a literature equation (LE) derived from a POPPK previously published. The Xgboost algorithm yielded numerically best performances and target attainment rates: 46.9% in the second simulation set of 400-600 AUC/MIC ratio vs. 41.4% for the LE model (p=0.0018); and 35.3% vs. 28% in real patients (p=0.401), respectively). The Xgboost model resulted in less AUC/MIC>600, thus decreasing the risk of nephrotoxicity.Secondly, we developed Machine learning (ML) algorithms trained on simulated pharmacokinetics profiles obtained by Monte Carlo simulations to estimate the best ganciclovir or valganciclovir starting dose in children; and we compared its performances on real-world profiles to previously published equation derived from literature POPPK models. A combination of Xgboost, neural network and random forest algorithms yielded the best performances leading to the highest target attainment in the test set (47.3% for ganciclovir and 50.5% for the valganciclovir). In actual patients, the best ML starting dose for valganciclovir yielded the highest target attainment rate (38.2%) while the second best for ganciclovir (22.6% for Franck Algorithm and 19.4% for ML dose).Thirdly, we developed and validated a ML-based limited sampling strategy (LSS) approach to determine GCV and VGCV AUC0–24 in children. The best estimation performances in the test set were obtained with the Xgboost algorithm and 2 and 6 hours post dose LSS for VGCV (rMPE=0.49%, rRMSE=7.27%) and 1 and 6 hours post dose LSS for GCV (rMPE= 0.49%, rRMSE=7.7%). In the external dataset, the performance based on 2 samples were acceptable: rMPE=2.8%, rRMSE= 16.6% for VGCV and rMPE=-10.7% , rRMSE=24.0% for GCV. The overall thesis allowed to clarify the advantages and disadvantages of ML algorithms for predicting the first doses of anti-infectives in children and for estimating the AUC of GCV or VGCV
Huchelmann, Alexandre. "Etude de l’implication des deux voies de biosynthèse des isoprénoïdes pour la spécificité et la régulation de la prénylation des protéines chez les plantes." Thesis, Strasbourg, 2013. http://www.theses.fr/2013STRAJ047.
Type-I protein prenylation is a post-translational modification of a protein bearing a CaaX motif with a prenyl moiety, this by a thioether linkage. The enzymes catalyzing those reactions are called protein prenyltransferase (PPTs). Two enzymes are involved, the protein farnesyltransferase (PFT) and the protein geranylgeranyltransferase type I (PGGT-I). They respectively use farnesyl diphosphate and geranylgeranyl diphosphate as substrate. Those precursors are synthetized in plants by two differentbiosynthetic pathways: the cytosolic mevalonate (MVA) and the plastidial methylerythritol phosphate (MEP) pathways. Protein geranylgeranylation is dependent of the MEP pathway. Those specificities can be modified A comparative analysis of PPTs specificity was done during this PhD thesis, revealing that PFT is specific for its protein substrate, while PGGT-I is specific for its prenyl substrate. But those specificities can be modulated in vivo, for instance by increasing the concentration of MVA. This suggests that the regulation of protein prenylation specificities can become functionally important during physiological processes. For that reason we characterized protein prenylation in elicited tobacco plants, which produce the sesquiterpene phytoalexin capsidiol. This metabolite is synthesized via the MVA pathway, and this process depends of protein prenylation, in particular geranylgeranylation, with the substrate coming from plastids. S-Carvone, a monoterpene, was identified as an inhibitor of PPTS, resulting in a lack of capsidiol production. This work also suggests that a new mechanism of prenylation might exist, specifically in leaves
Guesdon, William. "La cellule épithéliale intestinale dans l'induction des réponses immunitaires au cours de l'infection par cryptosporidium parvum : rôle des peptides antimicrobiens et des microARN." Thesis, Tours, 2014. http://www.theses.fr/2014TOUR4045.
The aim of my thesis was to study in the mouse model, the intestinal epithelial cell (IEC) response during neonatal Cryptosporidium parvum infection with a focus on microRNAs (miR) and antimicrobial peptides (AMP) response. C. parvum is a protozoan parasite that affects preferentially newborn, young or immunocompromised adult and completes its life cycle only in IECs. In a first part, we studied the expression of miRs in IEC during C. parvum infection. We compared the responses between in vitro infected IEC and IECs purified from infected neonatal mice and observed a decrease of miR-181d-5p expression. This reduced expression of miR-181d-5p was associated with an upregulation of the mRNA coding for two putative targets OPG and BCL2 which are anti-apoptotic agents that may favor parasite survival in IEC. This functional relation between miR-181d-5p and OPG was next demonstrated by using reporter dual-luciferase assay. In a second part of my thesis, we characterized the AMP expression profile and studied their role during C. parvum infection in neonates. We showed that infection up-regulates a broad expression of AMP except for CCL20 and CRAMP cathelicidin for which mRNA expression was decreased. We next choose to focus our work on these two molecules and reported that administration of CCL20 and CRAMP to infected neonatal mice significantly reduced the number of parasites in the intestine through a direct killing activity on free stages of the parasite. As the decreased expression of these two AMPs during infection seems to favor the development of the parasite, this could be an escape mechanism developed by C. parvum that may occur through the modulation of miR
Книги з теми "Agents anti-infectieux – Chez l'enfant":
Sahib, El-Radhi A., Carroll James 1945-, and Klein Nigel, eds. Clinical manual of fever in children. Berlin: Springer, 2009.
American Academy of Pediatrics Committee on Infectious Diseases. Red book: 2003 report of the Committee on Infectious Diseases. 2nd ed. Washington, D.C: American Academy of Pediatrics, 2003.
Sahib, El-Radhi A., Carroll James 1945-, and Klein Nigel, eds. Clinical manual of fever in children. Berlin: Springer, 2009.
A, Fisher Jeffrey. The plague makers: How we are creating catastrophic new epidemics-- and what we must do to avert them. New York: Simon & Schuster, 1994.
Klein, Nigel, James Carroll, and A. Sahib El-Radhi. Clinical Manual of Fever in Children. Springer, 2019.
Red Book 2009 Report Of The Committee On Infectious Diseases. American Academy of Pediatrics, 2009.